Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Novel endpoint evaluation of fluticasone propionate + salmeterol and components in COPD
2005-005602-23Phase 4Completed
- Sponsor
- GSK
- Start
- Jan 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of salmeterol + fluticasone, fluticasone propionate and salmeterol in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by GSK. Primary endpoint: Pre-dose R5-R15 by impulse oscillometry. Started Jan 2006; status: completed.
02
Drugs
salmeterol + fluticasonefluticasone propionatesalmeterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2005-005602-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005602-23.